← Back to Clinical Trials
Recruiting NCT06856538

NCT06856538 Rhomboid Intercostal Sub Serratus Plane Block Versus Serratus Anterior Plane Block in Thoractomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06856538
Status Recruiting
Phase
Sponsor Yasser S Mostafa, MD
Condition Thoracic
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-02-01
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
BupivacainUltrasound

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-02-01 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the current study is to compare the efficacy of the analgesic effect of ultrasound-guided unilateral Rhomboid intercostal and sub serratus plane block (RISS) versus Serratus anterior plane block (SAPB) in Thoracotomy incision.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18-70 years. * Patients scheduled for unilateral Thoracotomy. * American Society of Anesthesiologists (ASA) physical status I-III. * Patients who are candidates for general anesthesia. * No history of severe allergies to local anesthetics or other medications used during the procedure. Exclusion Criteria: * ASA PS class ≥ IV patients. * obese (BMI ≥ 35) patients. * Patients with uncontrolled cardiovascular. * patients with neurological deficits, cardiopulmonary, hepatorenal , or metabolic diseases; anticoagulants; any drug allergies. * Patients with emergency surgeries or re-do surgeries. * Systemic infections or infections at the site of injection. * Psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression). * Narcotic dependency.

Contact & Investigator

Central Contact

Emad El Mohamed Abd El-Razek, M.Sc.

✉ ema18@fayoum.edu.eg

📞 0 109 400 6418

Principal Investigator

Mahdy A Abdelhady, MD

STUDY CHAIR

Fayoum University

Frequently Asked Questions

Who can join the NCT06856538 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Thoracic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06856538 currently recruiting?

Yes, NCT06856538 is actively recruiting participants. Contact the research team at ema18@fayoum.edu.eg for enrollment information.

Where is the NCT06856538 trial being conducted?

This trial is being conducted at El Fayoum Qesm, Egypt.

Who is sponsoring the NCT06856538 clinical trial?

NCT06856538 is sponsored by Yasser S Mostafa, MD. The principal investigator is Mahdy A Abdelhady, MD at Fayoum University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology